Clinical Trial Update: Efficacy and Safety of Rituximab Combined With Omalizumab in Patients With Bullous Pemphigoid [Phase 3]

View source ↗

Summary

Phase 3 study evaluating rituximab in combination with omalizumab for bullous pemphigoid has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bullous Pemphigoid

Drugs mentioned

• Omalizumab (Omalizumab)
• Rituximab (rituximab)

Snippet

Sponsor: University of California, Davis | Conditions: Bullous Pemphigoid | Phase 3 | Status: WITHDRAWN